Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

NCT04717700

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Aalborg University Hospital Aalborg, Denmark
  • Sydvestjysk Sygehus Esbjerg Esbjerg, Denmark
  • Regionshospitalet Gødstrup Gødstrup, Denmark
  • Odense University Hospital Odense, Denmark
View Trial Details
Active, not recruiting

A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)

NCT04965155

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • AOU Ospedali Riuniti Umberto I Ancona, Italy
  • AOU Policlinico di Bari Bari, Italy
  • AOU di Bologna Bologna, Italy
  • Ospedale di Bolzano - Azienda Sanitaria dell'Alto Adige Bolzano, Italy
View all 14 locations
View Trial Details
Active, not recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

NCT04072458

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +40 more
Locations
  • Georgia Cancer Center Augusta, Georgia, United States
  • New York Medical College / Westchester Medical Center Valhalla, New York, United States
  • Sarah Cannon Research Institute/Tennesee Oncology Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Active, not recruiting

A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT06622226

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • National Hospital Organization Shibukawa Medical Center Shibukawa-shi, Gunma, Japan
  • Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital Hiroshima, Japan
  • National Hospital Organization Sendai Medical Center Sendai, Miyagi, Japan
View Trial Details
Active, not recruiting

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841

Conditions
Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • Sun Yat-sen University Cancer Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 13 locations
View Trial Details
Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

NCT03264131

Conditions
Adult T-Cell Leukemia/Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • South Broward/Memorial Healthcare System Hollywood, Florida, United States
  • Boston Medical Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States
  • Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
View Trial Details

Related conditions